Is Lexapro (escitalopram) or Wellbutrin (bupropion) better for treating anxiety and depression?

Lexapro (Escitalopram) is Superior for Anxiety and Depression

For patients presenting with both anxiety and depression, Lexapro (escitalopram) is the preferred first-line agent over Wellbutrin (bupropion). 1, 2

Primary Rationale

Escitalopram directly treats both anxiety and depression, while bupropion is contraindicated or ineffective for anxiety disorders. 1

• Escitalopram is specifically approved and recommended as a preferred first-line agent for depression with favorable adverse effect profiles 1
• Escitalopram demonstrates efficacy in generalized anxiety disorder, panic disorder, social anxiety disorder, and obsessive-compulsive disorder 3, 4
• Bupropion is only indicated for depression when significant psychiatric comorbidity exists, and higher doses of SSRIs like escitalopram are specifically recommended for patients with both anxiety and depression 1

Evidence for Escitalopram's Dual Efficacy

Escitalopram shows rapid onset of action on anxiety symptoms, with significant improvement appearing within 1-2 weeks of treatment. 4, 5

• In patients with depression and anxiety symptoms, escitalopram demonstrated significant superiority over placebo on anxiety measures (MADRS item 6, HAM-A) with improvement significant by week 1 (p<0.05) and highly significant by week 2 (p<0.001) 5
• The drug is effective across the anxiety spectrum in pediatric and adult populations, reducing anxiety symptoms in children as young as 7 years with GAD 6
• Venlafaxine (an SNRI) showed statistically significantly better response rates than fluoxetine for anxiety, but escitalopram remains preferred due to superior tolerability 1, 2

When Bupropion Has Limited Role

Bupropion should only be considered when anxiety is NOT present or when depression is the sole diagnosis. 1

• Guidelines explicitly state that higher doses of SSRIs or bupropion are indicated "only if the patient shows significant psychiatric comorbidity in the form of anxiety and depression," with SSRIs being the logical choice when both are present 1
• Bupropion has not been studied for anxiety disorders and lacks the serotonergic mechanism necessary for anxiolysis 1
• In treatment algorithms for comorbid anxiety-depression, switching to SNRIs (venlafaxine) is recommended over bupropion when escitalopram fails 2

Practical Prescribing Algorithm

Start escitalopram 10 mg daily, increasing to 20 mg after 4 weeks if partial response. 1, 2

• The therapeutic dose range is 10-20 mg daily, with 20 mg showing statistically significant superiority in anxiety reduction compared to placebo 2
• Allow 8-12 weeks at therapeutic dose before declaring treatment failure 2
• Absorption is rapid (peak levels in 3-4 hours), not affected by food, and steady-state is achieved in 7-10 days 7
• Once-daily dosing is appropriate due to the 27-33 hour half-life 7

Safety and Tolerability Advantages

Escitalopram has minimal drug interaction potential and favorable tolerability compared to other antidepressants. 3, 7

• Low protein binding (56%) reduces interaction risk with other medications 7
• Metabolized by three CYP isoenzymes (2C19, 2D6, 3A4), so impairment of one enzyme is unlikely to significantly affect clearance 3
• Common adverse effects (nausea, insomnia, diarrhea) are generally mild and transient, occurring at rates similar to placebo except for ejaculatory problems and nausea 4
• Escitalopram has six times less potency than citalopram at histamine H1 and muscarinic receptors, reducing anticholinergic side effects 3

Critical Caveat

Monitor for suicidality during the first months of treatment and after dose adjustments, particularly in younger patients. 2

• Behavioral activation or agitation may occur early in treatment, supporting gradual dose titration 2
• If anxiety worsens significantly in the first 1-2 weeks, this typically represents initial activation rather than treatment failure—continue treatment unless severe 5